Aliases & Classifications for Vaginal Disease

MalaCards integrated aliases for Vaginal Disease:

Name: Vaginal Disease 12 15
Vaginal Diseases 43 44 72

Classifications:



External Ids:

Disease Ontology 12 DOID:121
MeSH 44 D014623
NCIt 50 C26910
SNOMED-CT 68 25658005
UMLS 72 C0042251

Summaries for Vaginal Disease

MedlinePlus : 43 Vaginal problems are some of the most common reasons women go to the doctor. They may have symptoms such as Itching Burning Pain Abnormal bleeding Discharge One common problem is vaginitis, an inflammation of the vagina. Other problems that affect the vagina include sexually transmitted diseases, vaginal cancer, and vulvar cancer. Treatment of vaginal problems depends on the cause.

MalaCards based summary : Vaginal Disease, also known as vaginal diseases, is related to vaginitis and vaginal discharge, and has symptoms including pelvic pain and leukorrhea. An important gene associated with Vaginal Disease is CD4 (CD4 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Etonogestrel and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and uterus, and related phenotype is immune system.

Disease Ontology : 12 A female reproductive system disease that is located in the vagina.

Wikipedia : 75 A vaginal disease is a pathological condition that affects part or all of the... more...

Related Diseases for Vaginal Disease

Diseases related to Vaginal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 vaginitis 31.5 SPTB LAP3 IL6 IL1B DEFB4A CXCL8
2 vaginal discharge 11.0
3 leukoplakia of vagina 11.0
4 ventilation pneumonitis 10.6 TNF CD4
5 mycobacterium kansasii 10.6 FN1 CXCL8
6 recurrent corneal erosion 10.6 IL6 IL1B CXCL8
7 bagassosis 10.6 IL6 IL1B CXCL8
8 gastritis 10.6 IL1B DEFB4A CXCL8
9 funisitis 10.6 IL6 IL1B CXCL8
10 periodontitis, chronic 10.5 IL6 IL1B
11 scorpion envenomation 10.5 TNF IL6
12 acute transverse myelitis 10.5 IL6 CXCL8
13 staphylococcal toxic shock syndrome 10.5 TNF IL1B
14 newborn respiratory distress syndrome 10.5 IL6 IL1B CXCL8
15 exudative glomerulonephritis 10.5 TNF IL1B CXCL8
16 extrinsic allergic alveolitis 10.5 IL6 IL1B CXCL8
17 placenta disease 10.5 IL6 IL1B CXCL8
18 haemophilus influenzae 10.5 TNF IL1B CXCL8
19 opisthorchiasis 10.5 TNF IL1B CXCL8
20 bacterial pneumonia 10.5 IL6 DEFB4A CXCL8
21 crohn's colitis 10.5 TNF IL1B CXCL8
22 dental pulp disease 10.5 TNF IL1B CXCL8
23 esophagitis 10.5 IL6 IL1B CXCL8
24 tungiasis 10.5 TNF CXCL8
25 aseptic meningitis 10.5 TNF IL1B CXCL8
26 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 TNF IL6
27 peptic ulcer disease 10.4 TNF IL1B CXCL8
28 laryngitis 10.4 TNF IL6 IL1B
29 glossitis 10.4 TNF IL6 IL1B
30 acute vascular insufficiency of intestine 10.4 TNF IL6 IL1B
31 osteosclerotic myeloma 10.4 TNF IL6 IL1B
32 periapical periodontitis 10.4 TNF IL6 IL1B
33 poems syndrome 10.4 TNF IL6 IL1B
34 polyclonal hypergammaglobulinemia 10.4 IL6 CD4
35 autoimmune myocarditis 10.4 TNF IL6
36 silicosis 10.4 TNF IL1B CXCL8
37 streptococcal toxic-shock syndrome 10.4 TNF IL6 CXCL8
38 stachybotrys chartarum 10.4 TNF IL6 IL1B
39 central nervous system vasculitis 10.4 TNF IL6 IL1B
40 autoimmune gastritis 10.4 TNF IL6 IL1B
41 eales disease 10.4 TNF IL6 IL1B
42 endometritis 10.4 TNF IL6 IL1B
43 adult-onset still's disease 10.4 TNF IL6 IL1B
44 lacrimal apparatus disease 10.4 TNF IL6 IL1B
45 atrophic gastritis 10.4 TNF IL1B CXCL8
46 meconium aspiration syndrome 10.4 TNF IL6 CXCL8
47 commensal bacterial infectious disease 10.4 TNF IL6 IL1B
48 aphthous stomatitis 10.4 TNF IL6 IL1B
49 allergic contact dermatitis 10.4 TNF IL1B CXCL8
50 complex regional pain syndrome 10.4 TNF IL6 IL1B

Graphical network of the top 20 diseases related to Vaginal Disease:



Diseases related to Vaginal Disease

Symptoms & Phenotypes for Vaginal Disease

UMLS symptoms related to Vaginal Disease:


pelvic pain, leukorrhea

MGI Mouse Phenotypes related to Vaginal Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.32 CD101 CD4 FN1 IL1B IL6 LAP3

Drugs & Therapeutics for Vaginal Disease

Drugs for Vaginal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
2
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
3
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
4
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
7
Desogestrel Approved Phase 4 54024-22-5 40973
8
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
9
Azithromycin Approved Phase 4 83905-01-5 447043 55185
10
Desflurane Approved Phase 4 57041-67-5 42113
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
13
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
14
Polyestradiol phosphate Approved Phase 4 28014-46-2
15
Secnidazole Approved Phase 4 3366-95-8
16
Norethindrone Approved Phase 4 68-22-4 6230
17
Metronidazole Approved Phase 4 443-48-1 4173
18
Chlorquinaldol Approved Phase 4 72-80-0
19
Norethindrone enanthate Experimental Phase 4 3836-23-5
20 Antiviral Agents Phase 4
21 N-monoacetylcystine Phase 4
22 Respiratory System Agents Phase 4
23 Antidotes Phase 4
24 Free Radical Scavengers Phase 4
25 Antioxidants Phase 4
26 cysteine Phase 4
27 Expectorants Phase 4
28 Immunologic Factors Phase 4
29 Immune Sera Phase 4
30 Clindamycin palmitate Phase 4
31 Clindamycin phosphate Phase 4
32 Alkylating Agents Phase 4
33 14-alpha Demethylase Inhibitors Phase 4
34 Cytochrome P-450 CYP3A Inhibitors Phase 4
35 Antifungal Agents Phase 4
36 Cytochrome P-450 Enzyme Inhibitors Phase 4
37 Steroid Synthesis Inhibitors Phase 4
38 Cytochrome P-450 CYP2C9 Inhibitors Phase 4
39 Central Nervous System Depressants Phase 4
40 Progestins Phase 4
41 Anesthetics Phase 4
42 Anesthetics, General Phase 4
43 Platelet Aggregation Inhibitors Phase 4
44 Anesthetics, Inhalation Phase 4
45 Anti-Bacterial Agents Phase 4
46 Antiparasitic Agents Phase 4
47 Antiprotozoal Agents Phase 4
48 Anti-Infective Agents Phase 4
49 Estrogens Phase 4
50 Hormones Phase 4

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis Unknown status NCT03080740 Phase 4 Clindamycin palmitate hydrochloride dispersible tablet;Metronidazole Tablet
2 Randomised Control Trial of Probiotics Versus Placebo as Adjuvant to Oral Clindamycin Treatment for Bacterial Vaginosis During Pregnancy Unknown status NCT01558388 Phase 4 Lactobacillus acidophilus;Placebo
3 The Effects of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4 Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
4 Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis Unknown status NCT01841411 Phase 4 N-Acetyl cysteine;Metronidazole + N-Acetyl cysteine;metronidazole
5 Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole. Completed NCT00556179 Phase 4 Lactoserum (Dermacyd Femina®)
6 A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis Completed NCT02392026 Phase 4 Metronidazole Gel
7 Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis Completed NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
8 Extended Antimicrobial Treatment of Bacterial Vaginosis Combined With Human Lactobacilli to Find the Best Treatment and Minimize the Risk of Relapses Completed NCT01245322 Phase 4 lactobacilli
9 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 Shedding Completed NCT00464542 Phase 4 Metronidazole
10 Tinidazole for the Treatment of Bacterial Vaginosis Completed NCT00334633 Phase 4 tinidazole, metronidazole
11 Therapy and Prevention for Sexually Associated Bacterial Vaginosis Completed NCT00324818 Phase 4 metronidazole and azithromycin
12 Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy Completed NCT00642980 Phase 4 Clindamycin;Placebo;Clindamycin
13 Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity Completed NCT02445989 Phase 4 NuvaRing
14 Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial Completed NCT01800825 Phase 4 Clindamycin;Placebo
15 Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
16 A National, Multi-central, Open-label, Single-arm, Phase IV Study to Evaluate Efficacy and Safety of Gynomax® XL Ovule in the Treatment of Trichomonal Vaginitis, Bacterial Vaginosis, Candidal Vulvovaginitis and Mixed Vaginal Infections Recruiting NCT03839875 Phase 4 Gynomax® XL Vaginal Ovule
17 Postmenopausal Pessary Users: Estrogen Versus Trimosan Recruiting NCT03943823 Phase 4 Estrogen vaginal cream;Trimo-San vaginal gel
18 A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis Recruiting NCT03937869 Phase 4 Secnidazole
19 Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital Recruiting NCT03894813 Phase 4 "Probiotics" and "Metronidazole";Metronidazole Vaginal
20 A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis Recruiting NCT03099408 Phase 4 Metronidazole Oral;"Metronidazole" and "Lactobacillus"
21 Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda Recruiting NCT02905890 Phase 4 Norethisterone enantate
22 Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV) Recruiting NCT02042287 Phase 4 Metronidazole
23 The Use of Colposeptine in Bacterial Vaginosis. A Randomized, Controlled Study Terminated NCT01153958 Phase 4 Colposeptine;Metronidazole
24 Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis Unknown status NCT02173184 Phase 3
25 Phase II Multicentered Randomized Open-label Study of Effectiveness and Safety of Lactofiltrum in Women With Bacterial Vaginosis Unknown status NCT01089348 Phase 2, Phase 3 Lactofiltrum + Metronidazole;Metronidazole
26 Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis) Unknown status NCT00889356 Phase 3 Clindamycin 100mg and Ketoconazole 400mg;Tetracycline 100mg and Amphotericin B 50mg
27 VA-SENSE - BACTERIAL VAGINOSIS ONCE A WEEK SCREENING AND TREATMENT TO REDUCE INFECTIVE COMPLICATIONS, ABORTION AND PRETERM DELIVERY IN PREGNANT WOMEN WITH PREVIOUS PRETERM DELIVERY. Unknown status NCT01152528 Phase 3
28 Bacterial Vaginosis Screening and Treatment to Reduce Infective Complications, Abortion and Preterm Delivery Unknown status NCT00491270 Phase 3
29 The Effect of Probiotic Supplementation With Lactobacillus GR-1 and RC-14,on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients; a Randomised, Placebo Controlled Trial Unknown status NCT00536848 Phase 2, Phase 3 Metronidazole
30 A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02418845 Phase 3 SYM-1219;Placebo
31 A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis Completed NCT01621399 Phase 3 Product 55394;Placebo Vehicle (non-treatment)
32 A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets. Completed NCT00229216 Phase 3 Tinidazole
33 The Impact of Probiotic Bacteria on the Efficacy of Anti-retroviral Therapy and Recurrence of Bacterial Vaginosis Completed NCT01258556 Phase 2, Phase 3
34 Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus: A 52-Week Open-Label Follow-Up to Protocol 15-50310 Completed NCT01586364 Phase 3 Ospemifene 60Mg Oral Tablet
35 Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus: A 40 Week Randomized, Double Blind, Placebo Controlled, Follow-Up to Protocol 15-50310. Completed NCT01585558 Phase 3 Ospemifene (Dose 1);Ospemifene (Dose 2);Placebo
36 Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial Completed NCT01160796 Phase 3 placebo;Lcr35®
37 A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis Completed NCT03091777 Phase 3 GDC-229;Metronidazole Vaginal Gel 0.75%;Placebo
38 Phase III Comparative Study of Efficacy of 10 mg Dequalinium Chloride (Fluomizin) in the Local Treatment of Bacterial Vaginosis Completed NCT01125410 Phase 3 Dequalinium chloride;Clindamycin
39 A Phase 3b, Comparative and Randomized Study to Assess the Efficacy and Safety of an Intravaginal Ovule Combination of Ketoconazole and Clindamycin Compared With an Intravaginal Cream Combination of Tetracycline and Amphotericin B for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis, Either Mixed or Isolated Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
40 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577537 Phase 3 1% SPL7013 Gel;Placebo
41 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Assess the Efficacy and Safety of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis Completed NCT01577238 Phase 3 1% SPL7013 Gel;Placebo
42 Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity, Symptoms of Vulvar and Vaginal Atrophy (VVA), Associated With Menopause: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 60 mg Dose With Placebo in Postmenopausal Women Completed NCT00729469 Phase 3 Ospemifene 60 mg;Placebo
43 Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing Oral Ospemifene 30 and 60 Mg Daily Doses With Placebo Completed NCT00276094 Phase 3 Ospemifene 30 mg;Ospemifene 60 mg;Placebo;Nonhormonal vaginal lubricant
44 A Phase 3, Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis Completed NCT02452866 Phase 3 SYM-1219
45 Efficacy and Long-Term Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing 60 MG Oral Daily Dose of Ospemifene With Placebo Completed NCT00566982 Phase 3 Ospemifene 60 mg;Placebo
46 A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women Completed NCT02210689 Phase 3 clindamycin phosphate vaginal cream 2%
47 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis Completed NCT02237950 Phase 3 Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
48 A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis. Completed NCT02236156 Phase 3 Metronidazole oral tablets 500mg;1% SPL7013 Gel;Placebo gel
49 A Randomised Controlled Trial of Single Dose Tinidazole+Fluconazole Versus Longer Courses of Metronidazole+Clotrimazole in the Management of West African Women With Vaginal Discharge Completed NCT00313131 Phase 3 tinidazole+fluconazole vs metronidazole+clotrimazole
50 Home Screening for Bacterial Vaginosis to Prevent STDs Completed NCT00667368 Phase 3 Metronidazole

Search NIH Clinical Center for Vaginal Disease

Cochrane evidence based reviews: vaginal diseases

Genetic Tests for Vaginal Disease

Anatomical Context for Vaginal Disease

MalaCards organs/tissues related to Vaginal Disease:

41
Testes, Colon, Uterus, Bone, Cervix, Neutrophil

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Disease:

19
Vagina

Publications for Vaginal Disease

Articles related to Vaginal Disease:

(show top 50) (show all 113)
# Title Authors PMID Year
1
Combined vaginal administration of nystatin, diiodohydroxyquin, and benzalkonium chloride versus oral metronidazole for the treatment of bacterial vaginosis. 17
30895611 2019
2
Potential vaginal probiotics: safety, tolerability and preliminary effectiveness. 17
30882242 2019
3
Obstetric fistula: A challenge to public health. 17
30880741 2019
4
Implementation of HPV-based cervical cancer screening combined with self-sampling using a midwifery network across rural Greece. The GRECOSELF study. 38
31427275 2019
5
Increased risk of HPV-associated genital cancers in men and women as a consequence of pre-invasive disease. 38
30650180 2019
6
Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. 38
30982556 2019
7
Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study. 38
30827725 2019
8
Feasibility of Carbon Ion Radiotherapy in the Treatment of Gynecological Melanoma. 38
30804128 2019
9
Newly Isolated Lactobacilli strains from Algerian Human Vaginal Microbiota: Lactobacillus fermentum Strains Relevant Probiotic's Candidates. 38
29185234 2019
10
Can We Improve Vaginal Tissue Healing Using Customized Devices: 3D Printing and Biomechanical Changes in Vaginal Tissue. 38
30269139 2019
11
Compounding to Prevent and Treat Dysbiosis of the Human Vaginal Microbiome. 38
30384345 2018
12
Regulation of Herpes Simplex Virus 2 Protein Kinase UL13 by Phosphorylation and Its Role in Viral Pathogenesis. 38
29899106 2018
13
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. 38
28886907 2017
14
Novel ex vivo protocol using porcine vagina to assess drug permeation from mucoadhesive and colloidal pharmaceutical systems. 38
28697437 2017
15
Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. 38
28446260 2017
16
Vulvar and Vaginal Graft versus Host Disease: A Healthcare Clinic Initiative. 38
28503642 2017
17
Clinical analysis of cervical intraepithelial neoplasia with vaginal intraepithelial neoplasia. 38
28445274 2017
18
Role of Molecular Biology in Diagnosis and Characterization of Vulvo-Vaginitis in Clinical Practice. 38
29017160 2017
19
Biotherapeutic agents and vaginal health. 38
26757173 2016
20
Baboon vaginal microbial flora. 38
27198467 2016
21
Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. 38
27084683 2016
22
Magnetic resonance imaging of the vagina: an overview for radiologists with emphasis on clinical decision making. 38
26379324 2015
23
Clinical characteristics of non-squamous cell carcinoma of the vagina. 38
25594143 2015
24
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. 38
25693011 2015
25
Use of a Flexible Inflatable Multi-Channel Applicator for Vaginal Brachytherapy in the Management of Gynecologic Cancer. 38
26442213 2015
26
Global availability of data on HPV genotype-distribution in cervical, vulvar and vaginal disease and genotype-specific prevalence and incidence of HPV infection in females. 38
25987893 2015
27
Spray-dried powders enhance vaginal siRNA delivery by potentially modulating the mucus molecular sieve structure. 38
26347257 2015
28
[Group A streptococcal perineal infection in children]. 38
25456689 2014
29
Botryomycosis of the vulva: a case report. 38
24402357 2014
30
First clinical implementation of the Capri applicator. 38
24423857 2014
31
β-Glucan induces reactive oxygen species production in human neutrophils to improve the killing of Candida albicans and Candida glabrata isolates from vulvovaginal candidiasis. 38
25229476 2014
32
Application of shRNA-containing herpes simplex virus type 1 (HSV-1)-based gene therapy for HSV-2-induced genital herpes. 38
23845900 2013
33
[Laparoscopic radical hysterectomy after initial brachytherapy for stage IB1 cervical cancer: feasibility and results]. 38
24139815 2013
34
Nanopharmaceuticals for improved topical vaginal therapy: can they deliver? 38
23684936 2013
35
Laparoscopic radical hysterectomy after preoperative brachytherapy for stage IB1 cervical cancer: feasibility, results, and surgical implications in a large bicentric study of 162 consecutive cases. 38
22932859 2013
36
Clinical outcomes in international federation of gynecology and obstetrics stage IA endometrial cancer with myometrial invasion treated with or without postoperative vaginal brachytherapy. 38
22365625 2012
37
Subtotal vaginectomy for management of extensive vaginal disease in 11 dogs. 38
22292563 2012
38
Role of vulvar care guidelines in the initial management of vulvar complaints. 38
22227837 2012
39
Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. 38
22318147 2012
40
Effect of quadrivalent HPV vaccination on HPV related disease in women treated for cervical or vulvar/vaginal disease. 38
22454090 2012
41
A caprine herpesvirus 1 vaccine adjuvanted with MF59™ protects against vaginal infection and interferes with the establishment of latency in goats. 38
22511971 2012
42
Vaginal use of Ibuprofen isobutanolammonium (ginenorm): efficacy, tolerability, and pharmacokinetic data: a review of available data. 38
22844609 2012
43
Evaluation of the VITOM in digital high-definition video exocolposcopy. 38
21558961 2011
44
Overlooked diseases of the vagina: a directed anatomic-pathologic approach for imaging assessment. 38
21997983 2011
45
Validation of the ethnopharmacological use of Polygonum persicaria for its antifungal properties. 38
21834226 2011
46
Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. 38
24592002 2011
47
Vaginal microbiocoenosis and cytology of prepubertal and adolescent girls: their role in health and disease. 38
20143208 2010
48
Revisiting old vaginal topics: conversion of the Müllerian vagina and origin of the "sinus" vagina. 38
19598112 2009
49
Healthcare resource use and costs associated with cervical, vaginal and vulvar cancers in a large U.S. health plan. 38
18757080 2008
50
[Vulvar intraepithelial neoplasia: a current problem]. 38
19142526 2008

Variations for Vaginal Disease

Expression for Vaginal Disease

Search GEO for disease gene expression data for Vaginal Disease.

Pathways for Vaginal Disease

Pathways related to Vaginal Disease according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 TNF TLR7 SPTB SLPI IL6 IL1B
2
Show member pathways
13.32 TNF SPTB IL6 IL1B FN1 CXCL8
3
Show member pathways
12.83 TNF IL6 IL1B CXCL8 CD4
4
Show member pathways
12.56 TNF IL6 IL1B FN1 CD4
5
Show member pathways
12.52 TNF IL6 IL1B CD4
6
Show member pathways
12.3 TNF IL6 IL1B DEFB4A CXCL8
7
Show member pathways
12.27 TNF IL6 IL1B CXCL8
8
Show member pathways
12.24 TNF TLR7 IL6 CXCL8
9
Show member pathways
12.2 TNF IL6 IL1B CXCL8
10 12.15 TNF IL6 IL1B CXCL8
11
Show member pathways
12.02 TNF IL6 IL1B FN1
12 11.98 TNF IL6 IL1B CXCL8
13
Show member pathways
11.97 TNF TLR7 IL6 IL1B CD4
14 11.96 TNF IL6 GP5 CD4
15 11.92 TNF IL6 IL1B
16 11.91 IL6 IL1B FN1 CXCL8
17 11.89 TNF IL6 IL1B FN1 CXCL8
18 11.87 TNF IL1B CXCL8
19 11.85 TNF IL6 IL1B CXCL8
20 11.8 TNF IL6 IL1B FN1 CXCL8
21 11.77 IL6 IL1B CXCL8
22 11.76 TNF IL1B CD4 CD101
23 11.75 TNF IL6 IL1B GP5 CD4
24 11.73 TNF IL6 IL1B CXCL8
25 11.73 TNF IL6 IL1B FN1 CXCL8
26 11.7 TNF IL6 IL1B
27
Show member pathways
11.64 TNF IL6 IL1B CXCL8
28 11.62 TNF IL6 IL1B CXCL8
29 11.56 TNF IL6 IL1B CXCL8
30 11.5 TNF IL6 FN1
31 11.49 TNF IL6 IL1B CXCL8
32 11.47 TNF IL6 IL1B
33 11.47 TNF IL6 IL1B CXCL8
34 11.42 TNF TLR7 IL6 IL1B CD4
35
Show member pathways
11.38 TNF TLR7 IL6 IL1B FN1 DEFB4A
36 11.37 TNF IL6 IL1B
37 11.35 TNF IL6 IL1B
38 11.29 TNF IL6 IL1B
39 11.27 TNF IL6 IL1B
40 11.19 TNF IL6 IL1B CXCL8
41 11.02 TNF IL6 IL1B CD4
42 10.98 TNF IL6 IL1B FN1 CXCL8
43 10.89 TNF IL1B
44 10.54 TNF IL6 FN1 CXCL8

GO Terms for Vaginal Disease

Biological processes related to Vaginal Disease according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.92 TNF TLR7 IL6 IL1B CXCL8
2 positive regulation of DNA-binding transcription factor activity GO:0051091 9.81 TNF IL6 IL1B
3 cellular response to lipopolysaccharide GO:0071222 9.81 TNF IL6 IL1B CXCL8
4 defense response to Gram-positive bacterium GO:0050830 9.8 TNF IL6 DEFB4A
5 defense response to Gram-negative bacterium GO:0050829 9.79 IL6 DEFB4A CD4
6 positive regulation of T cell proliferation GO:0042102 9.74 IL6 IL1B CD4
7 regulation of protein phosphorylation GO:0001932 9.73 TNF TLR7 FN1
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.72 TNF TLR7 IL1B
9 embryonic digestive tract development GO:0048566 9.65 TNF CXCL8
10 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.65 TNF IL1B
11 negative regulation of lipid catabolic process GO:0050995 9.64 TNF IL1B
12 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.63 TNF IL1B
13 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 TNF IL1B
14 cytokine-mediated signaling pathway GO:0019221 9.63 TNF IL6 IL1B FN1 CXCL8 CD4
15 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.62 IL1B CD4
16 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.61 TNF TLR7
17 positive regulation of interleukin-8 production GO:0032757 9.61 TNF TLR7 IL1B
18 negative regulation of lipid storage GO:0010888 9.6 TNF IL6
19 positive regulation of chemokine biosynthetic process GO:0045080 9.59 TNF IL1B
20 response to glucocorticoid GO:0051384 9.58 TNF IL6
21 regulation of establishment of endothelial barrier GO:1903140 9.58 TNF IL1B
22 negative regulation of neurogenesis GO:0050768 9.58 TNF IL6 IL1B
23 positive regulation of interleukin-6 production GO:0032755 9.56 TNF TLR7 IL6 IL1B
24 positive regulation of fever generation GO:0031622 9.54 TNF IL1B
25 positive regulation of chemokine production GO:0032722 9.54 TNF TLR7 IL6
26 positive regulation of glial cell proliferation GO:0060252 9.5 TNF IL6 IL1B
27 sequestering of triglyceride GO:0030730 9.49 TNF IL1B
28 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 TNF IL1B
29 immune response GO:0006955 9.23 TNF TLR7 SLPI IL6 IL1B DEFB4A
30 chronic inflammatory response to antigenic stimulus GO:0002439 9.18 TNF
31 positive regulation of neuroinflammatory response GO:0150078 9.13 TNF IL6 IL1B

Molecular functions related to Vaginal Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 TNF IL6 IL1B CXCL8

Sources for Vaginal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....